CN112741836A - 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂 - Google Patents

用于运动机能亢进性运动障碍的治疗的vmat2抑制剂 Download PDF

Info

Publication number
CN112741836A
CN112741836A CN202011483141.5A CN202011483141A CN112741836A CN 112741836 A CN112741836 A CN 112741836A CN 202011483141 A CN202011483141 A CN 202011483141A CN 112741836 A CN112741836 A CN 112741836A
Authority
CN
China
Prior art keywords
htbz
isoquinolin
pyrido
hexahydro
dimethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011483141.5A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托弗·F·奥布赖恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CN112741836A publication Critical patent/CN112741836A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202011483141.5A 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂 Pending CN112741836A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
CN201580023821.XA CN106456629A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580023821.XA Division CN106456629A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Publications (1)

Publication Number Publication Date
CN112741836A true CN112741836A (zh) 2021-05-04

Family

ID=53264772

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202011483141.5A Pending CN112741836A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
CN202011483135.XA Pending CN112741835A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
CN201580023821.XA Pending CN106456629A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202011483135.XA Pending CN112741835A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
CN201580023821.XA Pending CN106456629A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Country Status (24)

Country Link
US (3) US20170071932A1 (enExample)
EP (3) EP3139925B1 (enExample)
JP (4) JP6635945B2 (enExample)
KR (5) KR20160147044A (enExample)
CN (3) CN112741836A (enExample)
AU (1) AU2015256012B2 (enExample)
CA (1) CA2947736C (enExample)
CY (1) CY1125058T1 (enExample)
DK (2) DK3936130T3 (enExample)
ES (2) ES2976207T3 (enExample)
FI (1) FI3936130T3 (enExample)
HR (2) HRP20240459T1 (enExample)
HU (2) HUE057839T2 (enExample)
IL (1) IL248745B (enExample)
LT (2) LT3139925T (enExample)
MX (1) MX387625B (enExample)
NZ (1) NZ725826A (enExample)
PL (2) PL3139925T3 (enExample)
PT (2) PT3936130T (enExample)
RS (2) RS65359B1 (enExample)
RU (1) RU2753740C2 (enExample)
SI (2) SI3139925T1 (enExample)
SM (2) SMT202400199T1 (enExample)
WO (1) WO2015171802A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075340A1 (en) 2015-10-30 2017-05-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
MA44127A (fr) 2015-12-23 2018-10-31 Neurocrine Biosciences Inc Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
WO2018001335A1 (zh) * 2016-06-29 2018-01-04 苏州科睿思制药有限公司 Nbi-98854的晶型及其制备方法和用途
EP4400171A3 (en) * 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
KR20230038601A (ko) 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 ｖｍａｔ2 억제제의 투여 방법
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
AU2018241940B2 (en) * 2017-04-01 2023-09-28 Adeptio Pharmaceuticals Limited Dihydrotetrabenazine for use in the treatment a movement disorder
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3057543A1 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
US20200179352A1 (en) * 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
SG11202004165UA (en) * 2017-11-08 2020-06-29 Yuhua Li Esters of dihydrotetrabenazine
CN110621674B (zh) 2017-12-26 2022-03-29 苏州科睿思制药有限公司 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
AU2019261403B2 (en) * 2018-04-25 2025-05-15 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
EP3806856A1 (en) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. METHOD OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
PH12021552745A1 (en) * 2019-05-09 2022-07-11 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008060451A2 (en) * 2006-11-09 2008-05-22 New York University Graded glass/zirconia/glass structures for damage resistant ceramic dental and orthopedic prostheses
CN101553487A (zh) * 2006-11-08 2009-10-07 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
CN103003275A (zh) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
CA2736409C (en) 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2015120317A1 (en) * 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553487A (zh) * 2006-11-08 2009-10-07 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
WO2008060451A2 (en) * 2006-11-09 2008-05-22 New York University Graded glass/zirconia/glass structures for damage resistant ceramic dental and orthopedic prostheses
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
CN103003275A (zh) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia", pages 1 - 2, Retrieved from the Internet <URL:https://www.prnewswire.com/news-releases/neurocrine-announces-phase-iib-results-of-vmat2-inhibitor-nbi-98854-for-treatment-of-tardive-dyskinesia-223015671.html> *
江文峰 等: "氘代作用在药物研究中的应用", 《齐鲁药事》, vol. 29, no. 11, pages 682 - 684 *

Also Published As

Publication number Publication date
JP2017514850A (ja) 2017-06-08
SMT202200193T1 (it) 2022-07-21
ES2976207T3 (es) 2024-07-26
SMT202400199T1 (it) 2024-07-09
EP3139925B1 (en) 2021-12-01
EP3936130A1 (en) 2022-01-12
RU2016147523A (ru) 2018-06-08
CN112741835A (zh) 2021-05-04
EP3139925A1 (en) 2017-03-15
US20200101063A1 (en) 2020-04-02
MX2016014429A (es) 2017-04-06
PL3139925T3 (pl) 2022-03-21
EP4389227A3 (en) 2024-09-04
JP2021191799A (ja) 2021-12-16
JP6635945B2 (ja) 2020-01-29
HRP20220025T1 (hr) 2022-04-01
KR20200133003A (ko) 2020-11-25
DK3139925T3 (da) 2021-12-20
RU2753740C2 (ru) 2021-08-23
PT3139925T (pt) 2022-01-26
NZ725826A (en) 2023-05-26
RS62782B1 (sr) 2022-01-31
CY1125058T1 (el) 2023-06-09
EP3936130B1 (en) 2024-02-14
HUE057839T2 (hu) 2022-06-28
LT3936130T (lt) 2024-04-25
KR20250029267A (ko) 2025-03-04
FI3936130T3 (fi) 2024-04-23
IL248745A0 (en) 2017-01-31
SI3936130T1 (sl) 2024-05-31
KR20160147044A (ko) 2016-12-21
CN106456629A (zh) 2017-02-22
KR20220140647A (ko) 2022-10-18
CA2947736A1 (en) 2015-11-12
EP4389227A2 (en) 2024-06-26
AU2015256012A1 (en) 2016-11-24
ES2904526T3 (es) 2022-04-05
KR20240011255A (ko) 2024-01-25
US20170071932A1 (en) 2017-03-16
PL3936130T3 (pl) 2024-06-10
IL248745B (en) 2022-07-01
US20210196702A1 (en) 2021-07-01
LT3139925T (lt) 2022-01-25
HUE066361T2 (hu) 2024-07-28
WO2015171802A1 (en) 2015-11-12
CA2947736C (en) 2023-04-18
JP2019218407A (ja) 2019-12-26
DK3936130T3 (da) 2024-03-25
JP2024153782A (ja) 2024-10-29
AU2015256012B2 (en) 2020-07-23
MX387625B (es) 2025-03-18
HRP20240459T1 (hr) 2024-06-21
PT3936130T (pt) 2024-04-17
RU2016147523A3 (enExample) 2018-12-28
SI3139925T1 (sl) 2022-04-29
RS65359B1 (sr) 2024-04-30

Similar Documents

Publication Publication Date Title
CN112741836A (zh) 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
US20190105314A1 (en) Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
EP2624821B1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
US11000519B2 (en) Pridopidine for treating drug induced dyskinesias
JP2017519827A (ja) ブスピロン代謝産物の使用
HK40111840A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
EP3664787B1 (en) Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
HK40067005A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303A1 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
KR20090031908A (ko) Ｓｌｖ308 및 ｌ-ｄｏｐａ를 포함하는 병용 제제
US20120172390A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination